News & Events

HaemaLogiX announces issuance of US patent for LMA

27 September 2022

Watch: Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process

15 August 2022

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

7 July 2022

HaemaLogiX announces issuance of USA patent for KMA.CAR T

7 July 2022

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

27 January 2022

HaemaLogiX welcomes Tertia Dex to the team

17 January 2022

HaemaLogiX welcomes Professor Simon Harrison to the SAB

21 December 2021

Full presentation materials on the novel antigens LMA and KMA at the 63rd annual ASH meeting are now available

15 December 2021

Dr Mary Sartor to present research on LMA and the 10B3 monoclonal antibody developed by HaemaLogiX at ASH 2021

5 November 2021

Platinum leads immuno-oncology company HaemaLogiX’s $10m capital-raising round

12 September 2021

HaemaLogiX raises $10 million to advance multiple myeloma treatments

8 September 2021

HaemaLogiX announces collaboration with the Peter MacCallum Cancer Centre

5 February 2021

Orphan Drug Designation for KappaMab transferred to HaemaLogiX

29 January 2021

HaemaLogiX announces issuance of Australian patent for LMA

22 January 2021

HaemaLogiX Announces the Outcomes of Two Innovation Connections Grant Projects

16 October 2020

Bryce Carmine to present at AusBiotech & Invest 2020

9 October 2020

HaemaLogiX announces results of collaboration with CellVec

2 October 2020

HaemaLogiX announces issuance of Australian patent for KMA.CAR

25 September 2020

Prof Andrew Spencer presents KappaMab Phase 2b interim analysis results at ASH 2019

8 December 2019

HaemaLogiX initiates collaboration with Universidad de Navarra

5 November 2019

HaemaLogiX initiates collaboration with TPL Path Labs

7 May 2019

KMA.CAR-T cell preclinical data poster presentation at AACR 2018

16 April 2018